Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Potential Buyers Reportedly Interested in Valeant’s OIC Treatment

By Ryan Bushey | August 9, 2016

Valeant Pharmaceuticals is reportedly in early talks to sell Relistor, a tablet for treating opioid-induced constipation.

Talks are in the early stages, according to Bloomberg, but a sale of this drug could help the embattled Canadian company chip away at its staggering $30 billion in debt. Sources told the publication Relistor could be valued between $400 million and $500 million.

Valeant paid an initial $50 million to Progenics Pharmaceuticals last month after the FDA approved the drug to help patients taking an opioid regimen deal with chronic, non-cancer pain. Progenics, a drug-maker that partnered with Valeant on developing the tablet form of Relistor, is entitled to receive an estimated $200 million in milestone payments based on sales of this therapy.

Valeant is hoping that Relistor could pose a threat to AstraZeneca’s similar drug Movantik, reported FiercePharma. An FDA approval helped, but analysts felt that blockbuster revenues aren’t guaranteed. Progenics predicted over $1 billion in peak sales for the pill version of Relistor. Analyst estimates, however, fluctuated between $125 million and $750 million.

Sources explained to Bloomberg Valeant could still back out of this rumored deal although the other assets could also be sold including the firm’s dermatology and pharmaceutical units.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50